Member Info for gtc1507

Https://www.linkedin.com/posts/fusion-antibodies-plc_trusted-antibody-partner-activity-7221454059940052993--3t1?utm_source=combined_share_message&utm_medium=member_ios

Fusion upping their marketing. Also, their LinkedIn saying that they are attending a big conference next week hopefully that will generate some more leads.

Some chat about the chart suggesting a breakout soon.

It looks like some positive news emerging from their investor portal questions too. Looking very rosy and undervalued ready for a move up soon we hope.

https://x.com/themoneysponge/status/1815722246226235550?s=46

Very bizarre. Does feel as if the MMs don’t want to give this a chance to recover.

Hopefully we’ll get some positive news from any of the awesome strands of work they’re focussed on and the true errata will happen.

Discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an Al-led approach to antibody drug design. This company has a market capitalisation of $535m and cash of $72m, so has an EV of $463m.

Reminded of some of the positives here:

1. Positive Q1 update, 100% up on last years same period with over 100% of FY23/24 revenues already on the order book for this year. https://tinyurl.com/2cchbyc8

2. Company chosen as the antibody partner for a billion dollar diagnostic company and generating multiple projects under a Master Service Agreement this year.

https://tinyurl.com/mpadxmas

3. Company’s unique and proprietary world class Human Antibody technology being tested and validated by the USA National Cancer Institute which couldn’t be a better partner to do so. If they successfully complete this will open door to massive licensing deal opportunities.

https://tinyurl.com/4mnahn27

4. CEO confirmed at the latest investor meets company meeting that they are one of a consortium of Life Sciences companies in Northern Ireland bidding for a large amount of grant funding which was looking more positive now government has returned and referenced in an NI government action plan for the sector recently published.

5. Company has developed new technologies to keep them at the cutting edge of industry, including their new licencable and low cost Optiphage technology https://tinyurl.com/z4vk55ke and their AI/ML antibody discovery technologies https://tinyurl.com/4967xdvr .

6. Company has received recent contracts from existing biotech client for their integrated service (https://tinyurl.com/bdz7r5my and https://tinyurl.com/5ext2cu6 where they retain royalty and milestone interests. CEO stated it’s possible that other milestones or royalties will be triggered in this year.

7. Company is diversifying into adjacent markets including vet med, diagnostics and research to broaden its existing VC funded base.

8. The VC base seems to be returning, with the XBI index hitting over $100USD demonstrating good recovery in the sector.

9. Company involved in project to develop unique algorithms for Fusion Antibodies with Oxford University Proteomics team, funded by UKRI Grant funding. https://tinyurl.com/5f2s5x9r

Overall, very encouraging prospects for the company and a definite buy at these prices. The most recent note from Allenby capital on their valuation sums it up for me…

Valuation

Fusion's market capitalisation is £3.3m, suggesting an EV of £2.1m, based on year £1.2m end cash. We consider this to represent an interesting special situation geared to the success of Fusion's recovery plan, where almost no value is currently being ascribed to its class leading antibody discovery technologies. This unusual situation has arisen as a result of the steep decline in revenue Fusion experienced in H2 FY23 that extended into FY24.

Given there is evidence of a turnaround in its fortunes and helped by an improved funding environment for biotech generally and its order book is now on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion's class leading antib

The fact this moves 30% on no news indicates where it’s going been there is news:

News due and positives:

- q1 revenues up 100% on last year and order book of 0.7m means they’ve already beat their 2023/24 revenues just 4 months in and potential for more massive contracts this year.

potential for receipt of part of £50m consortium funding from bid to create local life science powerhouse. CEO was confident and said would be very happy and popping champagne corks if it came off. NI executive just announced their June budget process had completed early in July so maybe this means we’re going to see movement soon?

- positive validation by $7bn funded US national cancer institute collaboration

- FAB chosen as antibody partner for Global Diagnostics company and multiple purchase orders being generated with more potential to come

- Oxford Uni project developing AI algorithms directly for Fusions utilisation.

- FAB diversifying into veterinary medicine market and presenting on their approach at Vet med conference in September

- multiple historic projects with milestones and royalties with potential to come off this year.

- significantly reduced cost base and cash runway to q2 2025 means no placing in sight and on track and on plan to be cash neutral before then.

All in all it

Taken from last Allenby capital broker note:

Given there is evidence of a turnaround in its fortunes and helped by an improved funding environment for biotech generally and its order book is now on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion's class leading antibody discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an Al-led approach to antibody drug design. This company has a market capitalisation of $535m and cash of $72m, so has an EV of $463m.

This was due a rerate. The company published very positive q1 update recently. Regardless of speculation about contracts and grants there is good news and massive potential here with the technologies and contracts they have as well as the NCI partnership. Hopefully we see an RNS in the morning

And this is all just one strand of their work.

Also major potential for positive developments from their partnership with USA National Cancer Institute ($7bn budget), the major global diagnostic company who have chosen FAB as their antibody partner and are generating multiple purchase orders or the plethora of companies who want to work with them.

It’s really an optimistic time for this company which their broker describes as undervalued and the SP ascribing no value to their world leading technologies

Https://tinyurl.com/2vvj8neu

More detail on the QUB website. At latest investor meet company CEO seemed confident it was nearly there and “will be popping champagne corks” with the others if it does come off.

I think they’re part of a consortium of about 9/10 companies bidding for £50m. I imagine they would get a decent amount but not the full £50m

What project that relate to? Is it the Future Medicine institute? About £50m?

What news do you believe is due?

Hardly an avalanche when only 0.6% of all shares traded today….and majority of trades are buys marked as sells by the algorithm

Link below broken

https://tinyurl.com/49uvhfyf

Great to see positive indication of government support for the future medicine institute in this.

FMI has potential for £50m grant funding according to this published info and Fusion is part of the consortium!

CEO said they would be popping champagne corks when this comes through.

https://www.qub.ac.uk/Business/futuremedicines/Filetoupload,1026773,en.pdf

Really interesting nuance there, targeting companies who are acquiring other companies antibodies and finding flaws in them. Good area of the market to target!

Interesting comment under this post

https://www.linkedin.com/posts/christopher-king-aa56b2282_poster-aim-lab-activity-7206326923193372672-diNq?utm_source=combined_share_message&utm_medium=member_ios

Big buy there - these buys are showing as sells on here today something fishy with the spread if we’re able to buy below mid market constantly

What price are you targeting?